Answers are grounded in this paper and cite their sources.
The recent approval of donanemab by Brazil's National Health Surveillance Agency (Agência Nacional de Vigilância Sanitária - Anvisa) in 20251 was met with enthusiasm by much of the medical community and by families of individuals living with Alzheimer's disease (AD). It was based on the results of a clinical trial that showed statistically significant differences in the rate of cognitive decline among individuals with early-stage AD.2 However, the results did not reach the minimum clinically important difference (MCID).
No takes yet. Share an insight, caveat, or question.
Castilhos et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: